Making better drugs: Decision gates in non-clinical drug development.
about
Mitochondrial disorders in children: toward development of small-molecule treatment strategiesGEMMs as preclinical models for testing pancreatic cancer therapiesZebrafish whole-adult-organism chemogenomics for large-scale predictive and discovery chemical biologyToxicology and drug delivery by cucurbit[n]uril type molecular containersEnabling large-scale design, synthesis and validation of small molecule protein-protein antagonistsEnhancement of CYP3A4 activity in Hep G2 cells by lentiviral transfection of hepatocyte nuclear factor-1 alphaPortfolio Decisions in Early DevelopmentCNS animal fMRI in pain and analgesia.Risk in CNS drug discovery: focus on treatment of Alzheimer's disease.A role for fMRI in optimizing CNS drug development.Screening for peptide drugs from the natural repertoire of biodiverse protein folds.The minipig as a new model for the evaluation of doxorubicin-induced chronic toxicity.Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.Phenotypic screening of phylomer peptide libraries derived from genome fragments to identify and validate new targets and therapeutics.Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform.Assessment of tandem mass spectrometry and high-resolution mass spectrometry for the analysis of bupivacaine in plasma.Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening on S. pombe Deletion Library.The potential of high-content high-throughput microscopy in drug discovery.Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?In vitro models: research in physiology and pharmacology of the lower urinary tract.Cellular imaging in drug discovery.Respirometric Screening Technology for ADME-Tox studies.Long-term culture and coculture of primary rat and human hepatocytesA review of imaging agent development.Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance.Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells.Weighted feature significance: a simple, interpretable model of compound toxicity based on the statistical enrichment of structural featuresA Predictive Model for Toxicity Effects Assessment of Biotransformed Hepatic Drugs Using Iterative Sampling Method.ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia.Engineering a perfusable 3D human liver platform from iPS cells.Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies.Modeling to optimize terminal stem cell differentiationCell and tissue engineering for liver disease.Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives.User-friendly 3D bioassays with cell-containing hydrogel modules: narrowing the gap between microfluidic bioassays and clinical end-users' needs.The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making.Applicability of plant-based products in the treatment of Trypanosoma cruzi and Trypanosoma brucei infections: a systematic review of preclinical in vivo evidence.The impact of molecular targets in cancer drug development: major hurdles and future strategies.Net present value approaches for drug discovery
P2860
Q26767327-EB807B3B-36D0-4C6B-BF66-141FBE3A6D86Q26781848-635BAEA0-E9CD-4408-8B9B-0035DEDF2991Q28473105-723D9886-48E5-4E2F-AB7D-AF62DE516E0BQ28473864-E9D7FBDB-B2A9-4632-8D35-C1153743F712Q28481449-4A49C07A-0C48-4EC4-93A3-6A3A58E37724Q28537869-A93DD2BC-E63D-491C-BCC7-2FF7CAB706EAQ29999056-2F561DE3-5821-48F5-992D-FDF109FD952FQ30469133-F4E72F71-737E-4CEB-806C-484835E5F670Q30855147-B3B1881C-A6B5-4664-B3BD-18189B24E999Q31036354-698AFAE8-5040-40E3-B6D1-27C50D229D21Q33233385-9043F57C-861C-4DC5-9B91-4269BDFFECE3Q33427938-E16733A9-FC4F-4950-B64C-B9AA78724F2AQ33748891-509A6647-62C2-414F-90C0-D60A52CCD9EEQ33852350-7711ECE2-4C82-4252-9EAC-199A232DFEEFQ33963735-13DDD651-6001-4056-9FB1-EC0A2DFB8874Q34367618-0A328A35-DBCC-45FD-8737-4DEE7A0E34A3Q35627328-1F678219-CF26-4AB8-BC71-D28CDEA36776Q35781121-9F6BA262-18EA-455B-8085-1F9A5FF81644Q35995251-062DD111-7895-4AC6-98D6-4683F56F51EBQ36179533-A1486430-BE67-453E-9212-850C4B379092Q36390257-3ED51322-2EF3-498C-BF77-7F24670A47B8Q36438745-2B552333-1A1F-4565-B0A3-BC72AEB8FD84Q36546284-A2A71C34-C85F-497E-AE31-6F944C5E7F92Q37193008-CD407EF1-1978-46EE-8085-EEDB26BECDCCQ37214528-90532258-5442-4569-B284-FF92C2141EA8Q37354141-CBC42139-1E06-4326-B23A-810A6B0133B4Q37402821-5B2B8DFF-9F2A-4B34-88A0-280FB7573BD9Q37420417-8024FA3B-5BEE-44E2-A89F-6417E861A433Q37487533-F3982C84-32C7-447F-839D-9CB2F4EDE577Q37535656-01ED0CEC-BC4A-4B90-B5E0-DF1665CC7841Q37655140-A1D076BA-F9AB-45C3-B62F-BADAE8637772Q38067621-FF7EE03E-56CC-4D74-A9A2-0AC760FB8893Q38166381-0AE9A07C-EB8A-4A74-8871-5AC11AD29D16Q38230357-812B789E-C1E4-42FC-92DE-1D89DEE92E21Q38334970-03C0AE89-2DC0-434C-BD48-3A083AF5A379Q38390835-6356F626-CFE4-4854-8192-2EB3691DD55EQ38911281-6075F6E7-1B38-4303-8B8A-C3887CFCC8ACQ39348896-BEF6731B-4658-4796-A33B-05C21E464A10Q39494507-DC03F18E-6315-4670-87A0-DB3C71F48584Q39753467-B6E9025E-2D55-4AA6-B8BF-4F01C0D5C346
P2860
Making better drugs: Decision gates in non-clinical drug development.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Making better drugs: Decision gates in non-clinical drug development.
@ast
Making better drugs: Decision gates in non-clinical drug development.
@en
type
label
Making better drugs: Decision gates in non-clinical drug development.
@ast
Making better drugs: Decision gates in non-clinical drug development.
@en
prefLabel
Making better drugs: Decision gates in non-clinical drug development.
@ast
Making better drugs: Decision gates in non-clinical drug development.
@en
P2093
P356
P1476
Making better drugs: Decision gates in non-clinical drug development.
@en
P2093
Brenda Rolfe
Elisabeth Mortimer
J Fred Pritchard
Malle Jurima-Romet
Mark L J Reimer
Mitchell N Cayen
P2888
P304
P356
10.1038/NRD1131
P577
2003-07-01T00:00:00Z